保健技术公司R1 RCM将由Tower Brook Capital Partners和Clayton、Dubiier & Rice以8.9bn美元购买,等待股东和监管批准。 Healthcare tech firm R1 RCM to be acquired by TowerBrook Capital Partners and Clayton, Dubilier & Rice for $8.9bn, pending shareholder and regulatory approval.
保健技术公司R1 RCM将由与Tower Brook资本伙伴公司和Clayton、Dubiier & Rice公司有联系的投资基金以8.9bn交易方式收购,该公司的价值为每股14.30美元。 Healthcare tech firm R1 RCM is to be acquired by investment funds linked to TowerBrook Capital Partners and Clayton, Dubilier & Rice in an $8.9bn deal, valuing the company at $14.30 per share. 收购需要股东和管理部门的批准,预计到年底将结束。 The acquisition, which requires shareholder and regulatory approval, is expected to close by the end of the year. R1 RCM向3 700多家医院和30 000名医生提供账单和税收服务。 R1 RCM provides billing and revenue collection services to over 3,700 hospitals and 30,000 doctors.